VINC vs. NMTR, TRVN, NAVB, EVFM, VIRX, ATXI, BPTSY, BIOR, MYMD, and KRBP
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include 9 Meters Biopharma (NMTR), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Evofem Biosciences (EVFM), Viracta Therapeutics (VIRX), Avenue Therapeutics (ATXI), Biophytis (BPTSY), Biora Therapeutics (BIOR), MyMD Pharmaceuticals (MYMD), and Kiromic BioPharma (KRBP). These companies are all part of the "pharmaceutical products" industry.
Vincerx Pharma vs.
Vincerx Pharma (NASDAQ:VINC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.
Vincerx Pharma's return on equity of -248.33% beat 9 Meters Biopharma's return on equity.
Vincerx Pharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.
Vincerx Pharma has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.
Vincerx Pharma currently has a consensus price target of $40.00, indicating a potential upside of 94,017.65%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Vincerx Pharma is more favorable than 9 Meters Biopharma.
9 Meters Biopharma received 16 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 65.63% of users gave Vincerx Pharma an outperform vote.
44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Vincerx Pharma beats 9 Meters Biopharma on 10 of the 13 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VINC) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy VINC Stock Free VINC Stock Alerts